Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Pheochromocytoma 1Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Everolimus 5pembrolizumab 2cabozantinib 2Trastuzumab 2Nivolumab 2vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1spartalizumab 1romidepsin 1regorafenib 1pentetreotide 1guadecitabine 1fostamatinib 1exemestane 1entrectinib 1entinostat 1belzutifan 1avelumab 1alectinib 1Vinorelbine 1Sirolimus 1Rosiglitazone 1Ritonavir 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Nephrectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × fostamatinib × Endocrine × Clear all
NCT00923481 2015-09-30

A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
37 enrolled 10 charts
EndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Neoplasms, Pheochromocytoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡